

2805.5 (PHA 4166.5)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of A. Moorman et al.
Serial No. TBA
Filed HERewith
Confirmation No. TBA
For METHOD FOR USING (H+/K+)ATPase INHIBITORS AS ANTIVIRAL
AGENTS
Examiner TBA

June 20, 2001

PRELIMINARY AMENDMENT A

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,

SIR:

Please enter the following amendments before examination of
the above referenced application:

IN THE SPECIFICATION

At page 1, following the Title of the Invention, please
insert the following paragraph:

--REFERENCE TO RELATED APPLICATIONS This application is a
continuation of Serial No. 09/605,560, filed June 27, 2000, which
is a continuation application of Serial No. 09/377,888, filed
August 19, 1999, which is a continuation application of Serial
No. 08/659,098, filed June 4, 1996, which is a continuation of
application serial No. 08/235,619, filed April 24, 1994.--

IN THE CLAIMS

Please add the following new claims 21-30:

21. A method of treating a viral infection in a subject, wherein the subject is infected with a DNA virus, the method comprising treating the subject with a therapeutically effective amount of a sulfur-containing (H^+/K^+) ATPase inhibitor.

22. The method of claim 21 wherein the inhibitor contains a divalent sulfur bridge.

23. The method of claim 21 wherein the inhibitor contains a sulfoxide.

24. The method of claim 21 wherein the subject is infected with a herpetoviridae virus.

25. The method of claim 24 wherein the herpetoviridae virus is selected from the group of viruses consisting of herpes simplex viruses, cytomegalovirus, herpes varicellazoster, Epstein-Barr, HHV6, HHV7, pseudorabies, and rhinotracheitis.

26. The method of claim 5 wherein the compound contains a divalent sulfur bridge.

27. The method of claim 5 wherein the compound contains a sulfoxide.

28. The method of claim 5 wherein the subject is infected with a DNA virus.

30. The method of claim 29 wherein the herpetoviridae virus is selected from the group of viruses consisting of herpes simplex viruses, cytomegalovirus, herpes varicellazoster, Epstein-Barr, HHV6, HHV7, pseudorabies, and rhinotracheitis.

2805.5 (PHA 4166.5)
PATENT

REMARKS

New claims 21-30 have been added. These claims are supported by the disclosure in the specification.

Accordingly, favorable consideration and early allowance of all pending claims is requested.

2805.5 (PHA 4166.5)
PATENT

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claim 21: NEW

Claim 22: NEW

Claim 23: NEW

Claim 24: NEW

Claim 25: NEW

Claim 26: NEW

Claim 27: NEW

Claim 28: NEW

Claim 29: NEW

Claim 30: NEW

2805.5 (PHA 4166.5)
PATENT

The Commissioner is hereby authorized to charge any
deficiency or overpayment of the required fee to Deposit Account
No. 19-1345.

Respectfully submitted,



Kathryn J. Doty, Reg. No. 40,593
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

Express Mail Label No. EL801508119US